CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Download All
Learn how global experts are leveraging the latest data on CDK4/6 inhibitors in patients with HR+/HER2- EBC. Watch the on-demand webcast from the live webinar, download the slides, and listen to the podcast featuring expert reviews of the most important data on early breast cancer from ESMO Breast 2021.
Javier Cortes, MD, PhD
Stephen R. D. Johnston, MA, FRCP, PhD
Sara Tolaney, MD, MPH

Downloadable Slidesets

Download this slideset to review the latest data on treatment for patients with HR+/HER2- early breast cancer.

Javier Cortes, MD, PhD Released: May 12, 2021

Download this slideset to review the latest data on adjuvant treatment for patients with HR+/HER2- early breast cancer.

Stephen R. D. Johnston, MA, FRCP, PhD Released: May 12, 2021

Download this slideset to review the latest data on neoadjuvant treatment and future considerations for patients with HR+/HER2- early breast cancer.

Sara Tolaney, MD, MPH Released: May 12, 2021

Download this short summary slideset of key takeaway points from a live presentation on the latest data on treatment for patients with HR+/HER2- early breast cancer.

Javier Cortes, MD, PhD Stephen R. D. Johnston, MA, FRCP, PhD Sara Tolaney, MD, MPH Released: May 14, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue